8-K
Forte Biosciences, Inc. (FBRX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2022
FORTE BIOSCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-38052 | 26-1243872 |
|---|---|---|
| (State or Other Jurisdiction<br> <br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br> <br>Identification No.) |
| 3060 Pegasus Park Dr.<br> <br>Building 6<br> <br>Dallas, Texas | 75247 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (310) 618-6994
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br> <br>Symbol(s) | Name of each exchange<br>on which registered |
|---|---|---|
| Common Stock, $0.001 par value | FBRX | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07. Submission of Matters to a Vote of Security Holders.
Forte Biosciences, Inc. (the “Company”) held its 2022 annual meeting of stockholders on June 1, 2022 (the “Annual Meeting”). Of the 14,761,261 shares of the Company’s common stock outstanding as of the record date of April 22, 2022, 8,322,250 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:
| 1. | Election of Class II Directors. The following nominees were elected to serve as Class II directors, each to hold office until the Company’s 2025 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified: | |||||
|---|---|---|---|---|---|---|
| Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||
| --- | --- | --- | --- | --- | --- | --- |
| Steven Kornfeld | 3,366,874 | 1,581,706 | 3,373,670 | |||
| Patricia Walker, M.D., Ph.D. | 3,335,739 | 1,612,841 | 3,373,670 | |||
| 2. | Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified based on the following results of voting: | |||||
| --- | --- | |||||
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
| --- | --- | --- | --- | |||
| 8,107,698 | 157,062 | 57,490 | — | |||
| 3. | Increase to the 2021 Equity Incentive Plan. The Company’s stockholders approved the increase to the shares reserved under the Company’s 2021 Equity Incentive Plan . The votes regarding the proposal were as follows: | |||||
| --- | --- | |||||
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
| --- | --- | --- | --- | |||
| 2,826,803 | 2,106,190 | 15,587 | 3,373,670 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INOGEN, INC. | ||
|---|---|---|
| Date: June 2, 2022 | By: | /s/ Antony Riley |
| Antony Riley<br> <br>Chief Financial Officer |